Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Find Clinical Drug Pipeline Developments & Deals by Laboratorium Ofichem B.V

Laboratorium Ofichem B.V

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Product List 2022, Corporate Presentation, GMP Certificate 2021, Product List 2021

VIDEO(s)

Corporate Video, World's Dependence on China's Medicinal Power, Ondernemen in Oost Groningen

DIGITAL CONTENT

29 News

29 News

APIs // Active Pharmaceutical Ingredients

40 APIs, 3 USDMF, 4 CEP/COS, 2 JDMF, 2 NDC API, 38 Listed APIs

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

KEY PRODUCTS

Dimethyl Fumarate, Histamine Dihydrochloride, Histamine Diphosphate Monohydrate, Methenamine Mandelate, Pamidronate, Phenylacetyl Disulfide, Potassium Bromide, Zinc Acetate

SERVICES

All Services, API Manufacturing, API & Drug Product Development

All Services
API Manufacturing
- 1 GMP Manufacturing
- 1 Small Scale Batch
API & Drug Product Development
- 3 API Development

KEY SERVICES

API Development Services, Small Scale Batch for APIs, API Small Scale Batch Manufacturing

INSPECTIONS & REGISTRATIONS

2 FDA, 1 EDQM, 1 GDUFA

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Laboratorium Ofichem B.V

Contact Supplier

Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

Contact Supplier

Contact Supplier

Digital Content

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Details:

Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healthy smokers.

Lead Product(s): Dimethyltryptamine

Therapeutic Area: Psychiatry/Psychology Product Name: EBRX-101

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Recipient: Entheon Biomedical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2021

Ofichem Company Banner

DCAT Week 2023

Attending

envelop Contact Supplier

POST ENQUIRY